Print

Geron Corporation (GERN) Presents Final Phase 1 Clinical Data on GRN1005 at American Association for Cancer Research-National Cancer Institute-European Center for Nuclear Research (CERN)  
11/15/2011 6:54:12 AM

MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced the final results of two Phase 1 clinical trials of GRN1005, the company’s lead LRP-directed peptide-drug conjugate (LRP-directed PDC), in patients with brain metastases from solid tumors and patients with malignant glioma, demonstrating preliminary but encouraging single agent clinical activity in both indications. Geron expects to initiate two Phase 2 clinical trials of GRN1005 before the end of the year in patients with brain metastases arising from breast cancer (Study GRN1005 Against Brain Metastases – Breast Cancer; GRABM-B) or non-small cell lung cancer (Study GRN1005 Against Brain Metastases – Lung Cancer; GRABM-L).
//-->